EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial)

Sebastian Giebel, Anna Czyż, Iwona Hus, Lidia Gil, Krzysztof Giannopoulos, Joanna Romejko-Jarosińska, Maciej Majcherek, Agnieszka Szeremet, Anna Wache, Paulina Kwaśnik, Ryszard Swoboda, Wojciech Jurczak

Annals of Hematology · 17.07.2026 · 105 (11)

DOI: 10.1007/s00277-026-07178-8 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Annals of Hematology, online erschienen am 17.07.2026. Verfasst von Sebastian Giebel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gliwice Branch, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland. sgiebel@io.gliwice.pl. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Hematopoietic Stem Cell Transplantation, Benzamides, Pyrazines. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca Pharma Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This phase 2 trial evaluated the safety and efficacy of acalabrutinib used to reduce tumor burden before allogeneic hematopoietic cell transplantation (allo-HCT) and as a maintenance therapy after transplantation in patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Patients were treated with acalabrutinib 100 mg BID for 3-6 months. Those achieving complete or partial response (CR, PR) were referred for allo-HCT. Acalabrutinib was restarted 30-90 days after allo-HCT and administered for the subsequent 9 months. The remaining patients continued acalabrutinib until progression or unacceptable toxicity. Out of the 28 included patients, 16 subjects (57%) responded, with CR in 14 cases (50%) and PR in 2 cases (7%). Fifteen patients (54%) underwent allo-HCT. Twenty-three patients (79%) had grade 3-4 adverse events, most commonly neutropenia (34%) and infections (21%). Five patients died of treatment-related toxicity, including infections in 4 cases. he probabilities of overall and progression-free survival (PFS) at 2 years were 60% (95%CI, 40-79) and 41.5% (23-60), respectively. PFS rate for patients treated with allo-HCT was 67% (44-92) at 18 months. Acalabrutinib generates high response rates in patients with R/R MCL and may serve as a "bridge" to allo-HCT and maintenance after transplantation. Infections are most frequent life-threatening complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellHematopoietic Stem Cell TransplantationBenzamidesPyrazinesAntineoplastic AgentsHumansMaleFemaleMiddle AgedAgedAdultPolandTransplantation, Homologous

Stichwörter der Autor:innen

AcalabrutinibAllogeneic hematopoietic cell transplantationMantle cell lymphomaRefractoryRelapsed

Substanzen

BenzamidesPyrazinesacalabrutinibAntineoplastic Agents

Autor:innen und Institutionen

  • Gliwice Branch, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland. sgiebel@io.gliwice.pl.
  • Department of Bone Marrow Transplantation and Onco-Hematology, Gliwice Branch, Maria Sklodowska-Curie National Research Institute of Oncology, Str. Wybrzeze Armii Krajowej, Gliwice, 44-102, Poland. sgiebel@io.gliwice.pl.
  • Wroclaw Medical University, Wroclaw, Poland.
  • National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland.
  • University Clinical Hospital, Poznań, Poland.
  • Medical University of Lublin, Lublin, Poland.

Förderung

  • AstraZeneca Pharma Poland

Zitieren

APA

Giebel, S., Czyż, A., Hus, I., Gil, L., Giannopoulos, K., Romejko-Jarosińska, J., Majcherek, M., Szeremet, A., Wache, A., Kwaśnik, P., Swoboda, R., & Jurczak, W. (2026). Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial). Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07178-8

Vancouver

Giebel S, Czyż A, Hus I, Gil L, Giannopoulos K, Romejko-Jarosińska J, et al. Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial). Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07178-8

BibTeX
@article{Giebel2026,
  author = {Giebel, Sebastian and Czyż, Anna and Hus, Iwona and Gil, Lidia and Giannopoulos, Krzysztof and Romejko-Jarosińska, Joanna and Majcherek, Maciej and Szeremet, Agnieszka and Wache, Anna and Kwaśnik, Paulina and Swoboda, Ryszard and Jurczak, Wojciech},
  title = {Acalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial)},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {11},
  doi = {10.1007/s00277-026-07178-8}
}
Kostenlos starten →